Oncorus Inc Quick Ratio (ONCR) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Oncorus Inc   (NASDAQ: ONCR)

Oncorus Inc 's Quick Ratio

ONCR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 0.68 a new company low.

Within Major Pharmaceutical Preparations industry 503 other companies have achieved higher Quick Ratio than Oncorus Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 2541 to 2623.

Explain Quick Ratio?
How much Cash & cash equivalents ONCR´s has?
What are ONCR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONCR Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change 156.14 % 77.4 % 36.3 % 49.07 % 79.42 %
Y / Y Cash & cash equivalent Change -71.9 % -74.48 % -71.45 % -46.98 % -56.26 %
Quick Ratio MRQ 0.68 0.69 2.47 5.29 6.22
ONCR's Total Ranking # 2623 # 2541 # 1269 # 1280 # 489
Seq. Current Liabilities Change -16.39 % 121.3 % 4.98 % 31.87 % -42.09 %
Seq. Cash & cash equivalent Change -17.47 % -38.15 % -50.98 % 12.3 % -25.05 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 504
Healthcare Sector # 908
Overall Market # 2623


Quick Ratio Statistics
High Average Low
26.11 9.91 0.68
(Dec 31 2020)   (Mar 31 2023)




Financial Statements
Oncorus Inc 's Current Liabilities $ 31 Millions Visit ONCR's Balance sheet
Oncorus Inc 's Cash & cash equivalent $ 21 Millions Visit ONCR's Balance sheet
Source of ONCR's Sales Visit ONCR's Sales by Geography


Cumulative Oncorus Inc 's Quick Ratio

ONCR's Quick Ratio for the trailling 12 Months

ONCR Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 79.98 % 61.7 % 89.29 % 122.42 % 157.52 %
Y / Y Cash & cash equivalent TTM Growth -64.03 % -60.69 % -50.26 % -21.32 % 19.78 %
Quick Ratio TTM 1.71 2.77 4.59 6.62 8.57
Total Ranking TTM # 4418 # 2669 # 705 # 185 # 3867
Seq. Current Liabilities TTM Growth 23.07 % 24.61 % 7.28 % 9.38 % 10.58 %
Seq. Cash & cash equivalent TTM Growth -23.86 % -24.8 % -25.58 % -15.59 % -16.78 %

Quick ratio ranking by company, industry and sector >> Back to ONCR Financial Strength Comparisons >> Go to Compare ONCR Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q1 2023 to $31.11 millions, cumulative Quick Ratio decreased to 1.71 below the Oncorus Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 582 other companies have achieved higher Quick Ratio than Oncorus Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 2669 to 4418.

Explain Quick Ratio?
How much Cash & cash equivalents ONCR´s has?
What are ONCR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 583
Healthcare Sector # 1156
Within the Market # 4418


trailing twelve months Quick Ratio Statistics
High Average Low
18.05 7.98 1.71
(Jun 30 2021)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Amphastar Pharmaceuticals Inc   1.85 $ 195.092  Millions$ 105.635  Millions
Cellectar Biosciences Inc   1.84 $ 12.683  Millions$ 6.905  Millions
Adlai Nortye Ltd  1.82 $ 91.492  Millions$ 50.317  Millions
Acadia Pharmaceuticals Inc   1.80 $ 402.873  Millions$ 224.301  Millions
Alzamend Neuro Inc   1.79 $ 5.141  Millions$ 2.870  Millions
Immunome Inc   1.79 $ 44.424  Millions$ 24.831  Millions
Aravive Inc   1.78 $ 35.924  Millions$ 20.192  Millions
Royalty Pharma Plc  1.77 $ 1,978.189  Millions$ 1,116.879  Millions
Nucana Plc  1.76 $ 28.478  Millions$ 16.153  Millions
Pacira Biosciences inc   1.76 $ 173.999  Millions$ 98.698  Millions
Endo International Plc  1.75 $ 1,060.652  Millions$ 606.643  Millions
Casi Pharmaceuticals inc   1.74 $ 29.094  Millions$ 16.726  Millions
Ayala Pharmaceuticals Inc   1.72 $ 16.947  Millions$ 9.833  Millions
Esperion Therapeutics Inc   1.70 $ 162.338  Millions$ 95.486  Millions
Palatin Technologies Inc   1.66 $ 19.632  Millions$ 11.851  Millions
Quantum Cyber N v   1.65 $ 17.929  Millions$ 10.892  Millions
Kiora Pharmaceuticals Inc   1.65 $ 3.426  Millions$ 2.083  Millions
Scorpius Holdings inc   1.64 $ 28.642  Millions$ 17.479  Millions
Impel Pharmaceuticals Inc   1.59 $ 35.465  Millions$ 22.282  Millions
Wave Life Sciences Ltd   1.57 $ 207.562  Millions$ 132.566  Millions
Bio Green Med Solution Inc   1.56 $ 11.435  Millions$ 7.338  Millions
Vaccinex Inc   1.55 $ 3.323  Millions$ 2.143  Millions
Sellas Life Sciences Group Inc   1.55 $ 24.002  Millions$ 15.511  Millions
Bgm Group Ltd  1.55 $ 8.476  Millions$ 5.481  Millions
Galectin Therapeutics Inc   1.54 $ 17.799  Millions$ 11.533  Millions
Entrada Therapeutics Inc   1.54 $ 227.648  Millions$ 147.594  Millions
Unicycive Therapeutics Inc  1.52 $ 24.332  Millions$ 15.970  Millions
Organigram Global Inc   1.51 $ 25.940  Millions$ 17.182  Millions
Nanobiotix S a   1.51 $ 84.317  Millions$ 55.858  Millions
Affimed N v   1.49 $ 43.152  Millions$ 29.016  Millions

Date modified: 2026-09-08T15:10:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.